Search - tctmd.com

Displaying 1 - 12 of 12

Sort: Relevancy | Date

Presentation TCT 2024

The Rise of AHA Target: Aortic Stenosis – Applying Quality Improvement Upstream of the Procedure (in partnership with the American Heart Association)

Presenter: Brian Lindman

October 30, 2024

Presentation TCT 2024

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

Presenter: Susheel Kodali

October 30, 2024

Presentation TCT 2024

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Presenter: Michael Reardon

October 30, 2024

Presentation TCT 2023

Clasp IID Updates and Complex Anatomy Registry

Presenter: Robert Smith

October 26, 2023

Presentation TCT 2023

Trancatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Randomized Clinical Trial (the VIVA Trial)

Presenter: Josep Rodés-Cabau

October 26, 2023

Presentation TCT 2023

Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation: Results From the Randomized TRILUMINATE Pivotal Trial

Presenter: Suzanne Arnold

October 26, 2023

Presentation TCT 2023

TRISCEND II: A Randomized Trial of Transcatheter Tricuspid Valve Replacement in Patients with Severe Tricuspid Regurgitation

Presenter: Susheel Kodali

October 26, 2023

Presentation TCT 2019

PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

Presenter: Raj Makkar

September 27, 2019

Presentation TCT 2019

PORTICO: A Randomized Trial of Portico vs. Commercially Available Transcatheter Aortic Valves in Patients With Severe Aortic Stenosis

Presenter: Gregory Fontana

September 27, 2019

Presentation TCT 2019

SCOPE I: A Randomized Trial of the ACURATE Neo vs. the SAPIEN 3 Bioprosthesis in Patients With Severe Aortic Stenosis

Presenter: Jonas Lanz

September 27, 2019

Presentation TCT 2016

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, Pamela S. Douglas

November 01, 2016

Presentation TCT 2016

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Presenter: Gregg W. Stone, Philippe Pibarot, David J. Cohen

November 01, 2016

Advertisement

The Rise of AHA Target: Aortic Stenosis – Applying Quality Improvement Upstream of the Procedure (in partnership with the American Heart Association)

TRISCEND II Trial: Transcatheter Valve Replacement vs. Optimal Medical Therapy for Severe Tricuspid Regurgitation

One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial

Clasp IID Updates and Complex Anatomy Registry

Trancatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis and Small Aortic Annuli: A Randomized Clinical Trial (the VIVA Trial)

Quality of Life After Transcatheter Tricuspid-Valve Repair vs. Medical Therapy in Patients with Severe Tricuspid Regurgitation: Results From the Randomized TRILUMINATE Pivotal Trial

TRISCEND II: A Randomized Trial of Transcatheter Tricuspid Valve Replacement in Patients with Severe Tricuspid Regurgitation

PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves

PORTICO: A Randomized Trial of Portico vs. Commercially Available Transcatheter Aortic Valves in Patients With Severe Aortic Stenosis

SCOPE I: A Randomized Trial of the ACURATE Neo vs. the SAPIEN 3 Bioprosthesis in Patients With Severe Aortic Stenosis

PARTNER I FIVE-YEAR ECHO: Long-term Hemodynamic and Structural Outcomes After Transcatheter Aortic Valve Replacement in High-Risk and Inoperable Patients With Aortic Stenosis

PARTNER II QUALITY OF LIFE: Health Status Benefits From a Prospective, Randomized Trial of Transcatheter and Surgical Aortic Valve Replacement in Intermediate-Risk Patients With Severe Aortic Stenosis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content